Mianserin

Quick links to important sections

Mianserin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mianserin

Property Description
Active Ingredient Mianserin (hydrochloride)
Form Oral film-coated tablet
Pharmacological Class Tetracyclic Antidepressant (TeCA); NaSSA
Common Use Relief of depressive symptoms
Origin Synthetic compound

Mianserin is a synthetic, single-ingredient medication classified as an Atypical Antidepressant, a type of psychoactive agent used to help regulate mood in individuals experiencing depressive illness. The drug is administered for use as an oral film-coated tablet and exerts its effect on the central nervous system. Its chemical structure formally places it within the Tetracyclic Antidepressant (TeCA) group, although its distinct mechanism of action leads to its functional classification as a Noradrenergic and specific Serotonergic Antidepressant (NaSSA).


Mianserin: Identity, Classification, and Composition

Mianserin is a synthetic compound derived from the piperazino-azepine chemical family. The active component is Mianserin, typically formulated as its hydrochloride salt and supplied as a racemic mixture of its two molecular forms, the S-(+) and R-(-) enantiomers. The Mianserin molecule is structurally characterized by its dibenzoazepine chemical framework.

Its classification as a NaSSA highlights its unique mode of action compared to agents that only target a single neurotransmitter. This action involves the simultaneous modulation of norepinephrine release and the blocking of specific serotonin receptors (5-HT2 and 5-HT3), providing a distinct pharmacological signature that is clinically recognized for its therapeutic profile in depression.


What is Mianserin's General Therapeutic Purpose?

The general purpose of Mianserin is to help relieve the symptoms of depressive illness by restoring a more stable chemical balance in the brain. The medicine works to normalize the neurotransmitter activity associated with mood disturbances.

Mianserin is particularly differentiating due to its potent antihistamine effect (blocking the H1 receptor), which is responsible for the drug's inherent sedative property. This hypnosedative property is often leveraged to address accompanying symptoms, such as significant anxiety, agitation, or insomnia, making it a recognized choice for patients whose depressive state includes such features.

What side effects are possible with Mianserin?

Possible Side Effects and Safety Information

The safety profile of Mianserin is categorized by the system-organ class affected and the frequency of the reactions reported in regulatory documents. The most commonly noted adverse reaction is drowsiness (somnolence), which is generally observed to be most prominent during the first few days of treatment.

Officially Documented Adverse Reactions

Adverse effects have been reported across several physiological systems. The official regulatory classification notes effects such as dizziness, tremor, postural hypotension, and disturbances of liver function (including jaundice) as having a frequency that cannot be precisely estimated from available data (Not Known).

Serious Adverse Reactions

Regulatory safety information highlights several clinically significant, though less frequent, risks. These include serious effects on the Blood and Lymphatic System such as bone marrow depression, which can manifest as agranulocytosis or granulocytopenia, and is most commonly reported after 4–6 weeks of exposure. The regulatory profile also documents the risk of suicide-related events, especially during the early stages of recovery or following dosage changes. The precipitation of hypomania and the occurrence of convulsions or a lowered convulsion threshold are also noted in official documents; the emergence of either of these conditions requires the official cessation of the medicine.

Population-Specific Safety Notes

Specific safety considerations are defined for certain groups in official labeling. Older people are noted to have a higher incidence of bone marrow depression. In children and adolescents (under 18), regulatory documents cite an increased frequency of suicide-related behaviour and hostility observed in clinical trials, resulting in a restriction on its use in this population.

Overdose and Emergency Response

Mianserin overdose is primarily characterized by central nervous system (CNS) effects. The most frequent manifestation is prolonged sedation and drowsiness. Other documented signs can include nausea or vomiting, dry mouth, dizziness, nystagmus (rapid eye movements), and changes in pupil size. More severe neurological outcomes listed in regulatory documents include convulsions (fits) and progression to coma.

The overdose profile also includes cardiovascular risks, such as alterations in heart rate (tachycardia or bradycardia) and blood pressure. Severe, life-threatening outcomes reported include changes in heart rhythm and cardiac arrest. However, certain severe effects like cardiac arrhythmics are explicitly stated as unlikely to occur.

Immediate medical help is required when an overdose is suspected. The official instruction is to contact a doctor or the nearest hospital emergency department immediately. The management approach is officially defined as symptomatic and supportive therapy, as no specific antidote is known. Procedural measures like gastric lavage may be utilized, and clinical monitoring is required.

Therapeutic Uses of Mianserin

Mianserin is applied across therapeutic domains where additional symptomatic support is relevant in contexts marked by increased discomfort or tension. It is commonly used in clinical settings that involve acute or unstable symptom patterns marked by periods of increased emotional and physiological tension. Mianserin is used for the treatment of symptoms of depressive illness.

Mianserin is relevant for managing major depressive disorder (MDD) and similar depressive conditions characterized by symptoms that create noticeable interference with daily stability. The therapeutic approach is commonly used to help with a cluster of symptoms, specifically low mood, inner agitation, and sleep disturbances.

Clinical Contexts: Relief for Accompanying Symptoms

Mianserin is commonly used in clinical scenarios where the depressive episode includes pronounced symptoms of anxiety and restlessness. Relevant in scenarios where additional management of discomfort is required, as it assists with maintaining functional stability and easing the overall symptom burden. This application provides support that may help patients cope more steadily with these difficult manifestations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mianserin?

The eligibility for Mianserin use is strictly defined by regulatory documents, distinguishing between those who are approved for use, those who require caution, and those who are absolutely excluded.


Populations for Whom Use is Contraindicated

Absolute prohibitions require that Mianserin must not be used by individuals with severe liver disease, a history of mania, or known hypersensitivity to the drug. It is also prohibited for patients currently receiving, or within two weeks of stopping, a Mono Amine Oxidase Inhibitor (MAOI).


Age and Physiological Restrictions

The medication is not recommended for children and adolescents under 18 years due to a lack of long-term safety data. Use in older adults requires close supervision and a lower initial dose. Mianserin is contraindicated for women who are breast-feeding and not recommended during pregnancy unless compelling reasons for its use exist.


Conditional Use with Caution

Caution is necessary and close monitoring is required for patients with comorbidities such as epilepsy (as the drug may lower the seizure threshold), severe kidney dysfunction, diabetes mellitus, and those with specific cardiac conditions including recent heart attack or heart block.

What should I know about interactions with other medicines?

Mianserin’s interaction profile is defined by restrictions on concurrent use with specific drug classes and conditions requiring close monitoring, as documented in regulatory prescribing information.

Interaction Type Interacting Agent(s) Official Constraint / Outcome
Prohibited / Restricted Mono Amine Oxidase Inhibitors (MAOIs) Co-administration is prohibited. Mianserin must not be started within two weeks of cessation of MAOI therapy. Avoid co-administration with Apraclonidine, Brimonidine, Sibutramine, and Artemether with lumefantrine.
Exposure Modification Carbamazepine, Phenobarbital These agents accelerate Mianserin’s metabolism, resulting in a reduced plasma concentration of the drug.
Pharmacodynamic Risk Alcohol, CNS Depressants Mianserin may potentiate the central nervous depressant action of alcohol and other CNS-acting medications like barbiturates, anxiolytics, and narcotic analgesics.
Monitoring Required Coumarin Anticoagulants Co-administration is permissible but requires close additional monitoring procedures of parameters such as prothrombin time.

Further regulatory caution is noted for combinations that may affect the seizure threshold. Mianserin may antagonise the anticonvulsant effect of antiepileptic medications. This caution is especially relevant during alcohol withdrawal or with co-administration of neuroleptics. Close monitoring of Phenytoin plasma levels is also required during concurrent use. This structure highlights the mandatory timing separation and the documented risks of altered drug levels or enhanced central effects.

Mechanism of Action

Mianserin’s mechanism of action is defined by its complex, multi-target profile within the central nervous system.

Dual Monoaminergic Disinhibition

The molecule blocks presynaptic alpha2-adrenergic receptors, which normally inhibit the release of norepinephrine and serotonin. This disinhibition removes the physiological inhibitory brake, resulting in a sustained enhancement of both neurotransmitter signals. This dual receptor antagonism is the core physiological change resulting from the multi-target interaction.

Specific Serotonin Receptor Modulation

Concurrently, Mianserin exerts antagonism at postsynaptic 5-HT2 A and 5-HT2 C receptors. This targeted receptor blockade refines the serotonergic signal by directing the increased synaptic serotonin toward preferential activation of the 5-HT1 receptor, establishing a specific serotonergic modulation within the central pathway.

H1 Histamine Receptor Blockade

A high-affinity mechanism involves the antagonism of the central Histamine H1 receptor. This molecular action rapidly suppresses the histaminergic arousal pathway, which produces the drug's inherent hypnosedative property via central nervous system suppression.

Dosage and Administration Information

How to Use Mianserin

Mianserin is typically presented as the hydrochloride salt for oral ingestion. It is available as a film-coated tablet formulation, commonly in 10 mg and 30 mg strengths.

Dosing and Schedule Principles

The standard adult treatment protocol begins with a daily starting dose of 30 mg. The dosage is adjusted, or titrated, based on individual response, generally within an effective maintenance range of 30 mg to 90 mg per day. The daily dose within the effective range generally reaches a maximum of 90 mg.

The daily amount may be administered as a single dose at night or divided into two or three sub-doses. Since the medication is often associated with a sedative effect, the single nightly dose is a common practice. The tablet is swallowed whole with fluid and may be taken irrespective of mealtimes.

Procedural Course and Population Rules

Treatment duration typically requires maintenance for several months after initial improvement is achieved to complete the therapeutic course. When discontinuing the medicine, the dosage is gradually reduced over time, as abrupt cessation is not the standard procedure.

Specific considerations apply to certain patient populations. For older adults, the starting dose remains at 30 mg daily, but subsequent dose increases are conducted slowly and under close supervision. Mianserin is not recommended for use in children and adolescents under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mianserin


Evidence for Use in Major Depressive Disorder and Related Illnesses

Mianserin was evaluated in studies exploring its use for conditions characterized by fluctuating or episodic manifestations of depressive illness. The research landscape is largely composed of short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Researchers examined outcomes related to physical discomfort and systemic or functional imbalance associated with depression, with measurements taken using standardized clinical scales. Short-term comparative studies reported patterns observed when measurements were compared against placebo or established standard therapies. These findings help contextualize how patients reported their experience during the study period.

Research on Accompanying Symptoms (Anxiety and Agitation)

Mianserin was observed in research exploring short-term symptom changes related to tension and agitation, which are common manifestations of depression. Studies specifically examined the effect on sleep disturbances and acute anxiety, monitoring physiological strain and patient-reported outcomes describing perceived discomfort. The evidence for these accompanying symptoms is largely derived from short-term trials where sample sizes were modest and comparative evidence is lacking against other specific treatments within the context of depression research.


Comparative Research and Study Design

The evidence base includes various RCTs and meta-analyses where research examined mianserin in comparison with standard antidepressant drugs. These studies monitored outcomes related to overall daily functioning or activity level. Data show patterns related to discontinuation or withdrawal rates across trials, with some participants choosing to withdraw at higher rates compared to specific comparator drugs. Results apply only to the populations studied, and long-term effects are not fully established by the comparative research.


The Study Landscape: Unanswered Questions and Limitations

A primary limitation is the focus on short-term treatment trials, as the majority of studies report outcomes based on a follow-up duration limited to eight weeks or less. This leaves limited information for long-term outcomes or how symptoms change during periods of maintenance treatment. The body of evidence includes a number of older trials where evidence quality varies across studies due to challenges in applying current scientific standards. Data for certain groups remain insufficient, and certainty remains low regarding sustained findings.

Key Studies & References

  1. Pharmacological treatments for treatment-resistant depression in adults: a systematic review and network meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Mianserin (FAQ)

Q: How does Mianserin work differently from an SSRI?

Official documents indicate that Mianserin's mechanism of action is distinct from Selective Serotonin Reuptake Inhibitors (SSRIs). Unlike SSRIs, Mianserin does not block the reuptake of serotonin. Instead, its primary action involves blocking presynaptic alpha-2-adrenergic receptors, leading to an increase in the release of certain brain chemicals.

Q: Is Mianserin an older medication?

Yes, regulatory and historical information suggests Mianserin is an older medication. Records show that the molecule was first synthesized in 1966 and was subsequently introduced to the market in certain regions in the late 1970s.

Q: Can Mianserin cause long-term weight gain?

According to the official product information, weight gain is a reported side effect of this medication. The possibility of this effect is noted in the adverse reactions section of regulatory documents.

Q: Are there any known withdrawal effects associated with stopping Mianserin?

Official regulatory information states that the dosage must be gradually reduced when discontinuing the medication. This procedure is followed to avoid potential unwanted side effects, which may include sweating, shaking, nausea, or anxiety. Serious outcomes like suicidal thoughts or behaviors have also been reported following the cessation of treatment.

Q: Does Mianserin affect blood pressure?

Official safety information lists postural hypotension as a possible side effect, which is a drop in blood pressure that occurs when standing up. Regulatory information states that close monitoring of blood pressure parameters may be required when Mianserin is used concurrently with anti-hypertensive drugs.

Q: Do the side effects of Mianserin typically lessen over time?

Studies and official information indicate that for some symptoms associated with depression, such as dry mouth and blurred vision, the frequency and severity have been observed to decrease during the course of treatment. The observation is that the severity of these effects has been reported to decrease.

Q: Will Mianserin help with sleep immediately?

Mianserin is known to have a marked sedative action due to its effect on the central nervous system. It is common practice for the total daily dose to be administered as a single dose at night due to the medication's favorable sedative effect on sleep.

Q: Is Mianserin considered suitable for long-term maintenance treatment?

Official documents state that treatment is often maintained for several months after the initial clinical improvement has been achieved. The suitability and duration of any maintenance treatment are determined on an individual basis.

Q: Does Mianserin affect blood sugar levels?

Yes, official safety data notes that hyperglycaemia, which means high blood sugar, has been reported as an adverse reaction following treatment with Mianserin.

Q: Is Mianserin a controlled substance?

The legal classification of Mianserin varies between countries. For instance, in the UK, it is classified as a Prescription Only Medicine (POM), while in other countries, such as Brazil, it may be classified as a controlled substance.

Q: Does Mianserin affect vision?

Official regulatory documents list blurred vision as a symptom that may be associated with treatment. This is often noted alongside other side effects that can decrease in severity over time.

Q: Can Mianserin cause dry mouth?

Dry mouth is listed in the official adverse reactions information as a symptom that may be associated with Mianserin treatment. Regulatory reports suggest the severity of this effect may decrease during the course of treatment.

Q: Can Mianserin cause restlessness or agitation?

Yes, official safety documents list restlessness and agitation among the possible side effects reported by patients.

Q: Are there specific foods or beverages to avoid when taking Mianserin?

While Mianserin can typically be taken with or without food, the use of alcohol with this medication is noted to potentiate the central nervous depressant action. This may potentially worsen drowsiness.

Q: Can Mianserin be taken safely with common pain relievers like ibuprofen or paracetamol?

Specific reports of interaction with non-prescription pain relievers like ibuprofen or paracetamol are not typically listed in the core regulatory documents. Official product information emphasizes the importance of checking all concurrent medications and supplements for potential interactions.

Q: Does Mianserin interact with herbal supplements like St. John's Wort?

Although a direct interaction with Mianserin may not be explicitly listed in all regulatory sections, official information regarding St. John's Wort notes the potential for interaction with antidepressant medications.

Q: What are the guidelines for Mianserin use if a dose is missed?

Official Patient Information Leaflets contain specific procedural guidance regarding how to manage a missed dose. This guidance outlines the timing for taking a dose that was forgotten and provides direction to avoid taking a double dose.

Q: How long does it typically take for Mianserin's full therapeutic effects to be noticed?

Clinical improvement may not be observed during the first few weeks or more of treatment. Official regulatory documents indicate that close monitoring is relevant during this initial period until clinical improvement is observed.

Q: Can Mianserin cause changes in appetite?

Yes, the official adverse reaction documentation lists increased appetite as a reported side effect of the medication.

Q: Does Mianserin have reported effects on sexual function?

Official safety documents list changes in sexual desire and sexual function among the other potential side effects that have been reported by patients.

Q: How does Mianserin affect driving ability or operating machinery?

Official warnings state that the ability to drive or operate machinery may be impaired due to the very common side effect of drowsiness. This effect is often most prominent during the early stages of treatment.

How should Mianserin be stored and disposed of?

How to Store and Dispose of Mianserin?

Official Storage Conditions

Mianserin tablets must be stored according to regulatory requirements to maintain product stability. The official requirement is to store the tablets below 30°C and keep them out of the sight and reach of children. The product requires protection from environmental factors; therefore, it must be stored away from direct sunlight, light, and moisture. Containers should be kept tightly closed to preserve the 3-year shelf-life.

Disposal Instructions

Disposal must follow regulatory protocols. The best option for discarding unused or expired mianserin is to use a drug take-back program when available. Mianserin is not on the list of medicines recommended for flushing down the sink or toilet. If household disposal is necessary, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag before being thrown into the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mianserin found in:

A-Z Index: